Exponential View: Why the Impact of GLP-1 May Surpass AI

Azeem Azhar writes that the impact of GLP-1 drugs may surpass that of AI; sales reached $76 billion by the end of 2025, exceeding generative AI's approximately $63 billion; the usage rate among American adults rose from 3% in 2024 to 11%. The article outlines the price collapse (monthly cost for Indian generics is about $13, 99% lower than the original price), the fact that about half of users stop taking the medication within a year, and potential spillover effects such as alcohol cessation and slowed heart aging, describing it as a form of societal restraint technology.